Verona Pharma plc Verona Pharma To Present At H.C. Wainwright Virtualbioconnect Conference

 
TIDMVRP 
 
   LONDON and RALEIGH, N.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Verona 
Pharma plc (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage 
biopharmaceutical company focused on respiratory diseases, announces 
that David Zaccardelli, Chief Executive Officer and President, will 
present a company overview at the H.C. Wainwright Virtual BioConnect 
Conference. The presentation will be available on-demand starting at 
8:00 AM ET on Monday, January 11, 2021. 
 
   A webcast of the event will be available for 30 days on the Events and 
Presentations link on the Investors page of the Company's website, 
www.veronapharma.com. 
 
 
 
 
  Verona Pharma plc                               Tel: [phone] 
----------------------------------------------  --------------------------- 
  Victoria Stewart, Director of Communications    [e-mail] 
----------------------------------------------  --------------------------- 
 
  Argot Partners                                  Tel: [phone] 
   (US Investor Enquiries)                         [e-mail] 
----------------------------------------------  --------------------------- 
  Kimberly Minarovich / Michael Barron 
----------------------------------------------  --------------------------- 
 
  Optimum Strategic Communications                Tel: [phone] 
   (European Media and Investor Enquiries)         [e-mail] 
----------------------------------------------  --------------------------- 
  Mary Clark / Eva Haas / Shabnam Bashir 
----------------------------------------------  --------------------------- 
 
 
   About Verona Pharma 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. If 
successfully developed and approved, Verona Pharma's product candidate, 
ensifentrine, has the potential to be the first therapy for the 
treatment of respiratory diseases that combines bronchodilator and 
anti-inflammatory activities in one compound. The Company is evaluating 
nebulized ensifentrine in its Phase 3 clinical program ENHANCE 
("Ensifentrine as a Novel inHAled Nebulized COPD thErapy") for COPD 
maintenance treatment. The Company raised gross proceeds of $200 million 
through a private placement in July 2020 and expects the funds to 
support its operations and Phase 3 clinical program into 2023. Two 
additional formulations of ensifentrine are currently in Phase 2 
development for the treatment of COPD: dry powder inhaler ("DPI") and 
pressurized metered-dose inhaler ("pMDI"). Ensifentrine is being 
evaluated in a pilot clinical study in patients hospitalized with 
COVID-19 and has potential applications in cystic fibrosis, asthma and 
other respiratory diseases. For more information, please visit 
www.veronapharma.com. 
 
   Forward-Looking Statements 
 
   This press release contains forward-looking statements. All statements 
contained in this press release that do not relate to matters of 
historical fact should be considered forward-looking statements. These 
forward-looking statements are based on management's current 
expectations. These statements are neither promises nor guarantees, but 
involve known and unknown risks, uncertainties and other important 
factors that may cause our actual results, performance or achievements 
to be materially different from our expectations expressed or implied by 
the forward-looking statements. Any such forward-looking statements 
represent management's estimates as of the date of this press release. 
While we may elect to update such forward-looking statements at some 
point in the future, we disclaim any obligation to do so, even if 
subsequent events cause our views to change. These forward-looking 
statements should not be relied upon as representing our views as of any 
date subsequent to the date of this press release. 
 
 
 
 

(END) Dow Jones Newswires

January 05, 2021 02:00 ET (07:00 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.